uniQure (QURE) Q2 2026 earnings review
A Massive Regulatory Reversal Rescues the U.S. Launch Path
uniQure management snatched victory from the jaws of regulatory defeat this quarter. After spending the last six months pivoting to Europe because the FDA demanded a new, lengthy sham-controlled trial for its lead Huntington's asset (AMT-130), the FDA blinked. Following a Type B meeting, the agency agreed that a BLA submission based on existing data under the accelerated approval pathway is reasonable. This completely rewrites the investment narrative. A $259M equity raise further bulletproofs the balance sheet, extending the cash runway to 2030. While net loss optically doubled YoY to $81.1M, this was driven by non-cash macro and warrant adjustments, not operating cash burn.
🐂 Bull Case
The FDA's agreement to accept a BLA filing in Q3 2026 for accelerated approval removes the massive overhang of a multi-year delay. The U.S. market is back in play for a near-term launch.
With $810.3M in cash following an upsized $259M public offering, uniQure has extended its runway into 2030, virtually eliminating near-term financing risk ahead of AMT-130 commercialization.
🐻 Bear Case
The FDA requires the AMT-130 confirmatory study to be 'well underway, and potentially fully enrolled' at the time of accelerated approval. Enrolling a randomized trial when the drug is commercially available is notoriously difficult.
AMT-191 (Fabry) remains paused at higher doses due to liver enzyme elevations, and the initial AMT-260 (Epilepsy) cohort showed highly bifurcated efficacy results.
⚖️ Verdict: 🟢🟢
Bullish. The FDA reversal on AMT-130 is a binary, thesis-altering positive event. The combination of a clear U.S. regulatory path and a heavily fortified balance sheet outweighs early-stage pipeline noise.
Key Themes
The FDA Pivot on AMT-130
In Q1 2026, management warned that the FDA strongly recommended a new, sham-controlled study before a U.S. filing, forcing the company to target the U.K. first. The Q2 update reveals a complete reversal: the FDA now agrees that filing for accelerated approval using existing data is 'reasonable.' This immediately resets the timeline, targeting a Q3 2026 BLA submission and moving potential U.S. commercialization forward by years.
The Confirmatory Trial Catch-22
While the FDA granted the accelerated approval pathway, they attached a heavy string: the confirmatory study must be well underway or fully enrolled by the time of approval. The FDA also requested a 'randomized standard-of-care control design.' Executing this trial concurrently with a commercial launch presents significant logistical and ethical challenges—patients rarely volunteer for a control arm if they can access the therapy commercially.
AMT-260 Efficacy Bifurcation
Preliminary 6-month data on the first low-dose cohort (6 patients) for AMT-260 (mesial temporal lobe epilepsy) showed extremely polarized outcomes. Three patients achieved 79% to 100% seizure reductions, but the other three ranged from a 33% decrease to a 36% increase. While the safety profile remains favorable, this bimodal response requires explanation as the second cohort completes enrollment.
AMT-191 Safety Pause Persists
The Phase I/II study of AMT-191 in Fabry disease remains formally paused at the mid- and high-dose cohorts. While the previously reported asymptomatic Grade 3 liver enzyme elevations resolved with immunosuppression by May 2026, the FDA and management have not yet greenlit resuming dose escalation, limiting near-term upside for this asset.
Macro Impact: Massive FX and Warrant Hit
A severe non-operating expense swing crushed Q2 net income. Net non-operating items shifted by $33.6M YoY to a $27.0M loss. This was driven by a $20.4M unfavorable net foreign currency swing and a $16.0M loss from changes in the fair value of pre-funded warrant liabilities. While non-cash, it highlights macroeconomic sensitivity on the balance sheet.
Pre-Launch Spend Accelerating
Management is heavily telegraphing their confidence in an imminent launch through their spending. SG&A expenses spiked $3.9M (+29% YoY) to $17.4M, explicitly driven by commercial infrastructure hiring for AMT-130. R&D spending actually fell slightly YoY (-$1.4M) to $34.0M, showing disciplined resource allocation away from earlier stages and toward commercial readiness.
Other KPIs
Reversing optically. The loss widened from $37.7M a year ago and $53.5M last quarter. However, operating loss only increased modestly ($52.2M vs $43.9M YoY). The bulk of the deterioration came from non-operating, non-cash items—specifically foreign exchange losses and warrant fair value adjustments.
Accelerating. Up from $2.2M a year ago. Management attributed a $6.0M increase explicitly to the costs associated with supplying the HEMGENIX product to CSL Behring.
Guidance
Accelerating. Previous guidance in Q1 2026 projected runway only into H2 2029. The successful $259M follow-on offering extended this materially, guaranteeing funding past the critical AMT-130 commercialization phase and mitigating dilution risk.
Accelerating. This is a massive improvement from prior quarters where the timeline was listed as 'uncertain' or dependent on new trials. The U.K. MHRA submission remains on track concurrently for Q3 2026.
Stable. The release of four-year follow-up data for the first 24 patients (12 high-dose, 12 low-dose) is locked in for September. This will be the ultimate validation event ahead of the FDA review.
Key Questions
The Confirmatory Trial Execution
Given the FDA's requirement that a confirmatory standard-of-care control study be 'fully enrolled' by the time of accelerated approval, how do you practically incentivize U.S. patients to enter a randomized trial when they know the drug will soon be commercially available?
AMT-260 Efficacy Disconnect
In the AMT-260 low-dose cohort, three patients saw near-total seizure elimination while three saw virtually no benefit. Have you identified any baseline biomarkers, patient history, or anatomical differences that explain this bimodal response?
AMT-191 Safety Next Steps
The liver enzyme elevations in AMT-191 resolved by May. What specific data or timelines are required by the FDA before you are permitted to resume dosing in the mid- and high-dose cohorts?